Physician profile
Rhiannon M Fahey
NPI 1376935692
$11,410.04
in general payments reported to CMS, 2019-2025
70 companies · $4,165 in 2025
The $4,165 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,551 · 2022: $2,443 · 2023: $1,619 · 2024: $1,632 · 2025: $4,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,297 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,297.15 |
| Education | $119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,214.33 | 2021-2025 | Rybrevant, Carvykti, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $654.98 | 2021-2025 | Enhertu, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $641.82 | 2022-2025 | |
| Daiichi Sankyo INC. | $613.81 | 2021-2025 | Enhertu, Datroway |
| Incyte Corporation | $603.32 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $490.60 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $477.71 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $433.48 | 2021-2025 | |
| Genzyme Corporation | $413.13 | 2021-2025 | |
| Astellas Pharma US INC | $333.43 | 2021-2025 | Xtandi, Vyloy, Padcev |
| Pfizer INC. | $313.34 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $295.69 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Eisai INC. | $280.23 | 2021-2024 | |
| Seagen INC. | $277.16 | 2021-2023 | Tukysa, Padcev |
| Gilead Sciences, INC. | $257.17 | 2021-2025 | Trodelvy |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $241.30 | 2022-2025 | Libtayo |
| Glaxosmithkline, LLC. | $223.01 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $220.06 | 2021-2023 | Lumakras |
| Pharmacyclics LLC, An Abbvie Company | $212.64 | 2021-2023 | Imbruvica |
| Beigene USA, INC. | $178.24 | 2022-2023 | Brukinsa |
| Kite Pharma, INC. | $168.93 | 2022-2025 | Yescarta |
| Lilly USA, LLC | $162.88 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Puma Biotechnology, INC. | $151.68 | 2021-2025 | Nerlynx |
| Takeda Pharmaceuticals U.S.A., INC. | $144.00 | 2023-2025 | Fruzaqla, Alunbrig |
| Emd Serono, INC. | $142.58 | 2022-2025 | |
| Geron Corporation | $133.70 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $119.38 | 2021-2025 | Fotivda |
| Jazz Pharmaceuticals INC. | $118.34 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $114.61 | 2023-2025 | Orgovyx |
| Adaptive Biotechnologies Corporation | $108.27 | 2022-2025 | Clonoseq |
| Sobi, INC | $102.94 | 2023-2025 | |
| Celgene Corporation | $101.42 | 2021-2023 | Reblozyl |
| Ipsen Biopharmaceuticals, INC | $96.53 | 2022-2025 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $93.78 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Legend Biotech USA INC. | $89.46 | 2024-2025 | Carvykti |
| Stemline Therapeutics INC. | $80.55 | 2024-2025 | Orserdu |
| Myovant Sciences INC. | $66.47 | 2021-2022 | |
| Tersera Therapeutics LLC | $61.38 | 2022-2025 | Zoladex |
| Agios Pharmaceuticals, INC. | $58.24 | 2024-2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $55.42 | 2022-2024 | |
| Dendreon Pharmaceuticals LLC | $55.40 | 2022-2025 | Provenge |
| Medtronic, INC. | $50.59 | 2022 | |
| Apellis Pharmaceuticals, INC. | $49.31 | 2022-2023 | Empaveli |
| Servier Pharmaceuticals LLC | $46.84 | 2021-2022 | |
| Kyowa Kirin, INC. | $45.33 | 2021-2025 | |
| Eusa Pharma (US) LLC | $41.79 | 2022 | |
| Genentech USA, INC. | $39.40 | 2022-2023 | Phesgo, Kadcyla, Perjeta |
| Pharmacosmos Therapeutics INC. | $37.91 | 2024-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $36.05 | 2022-2025 | Gavreto, Rezlidhia, Tavalisse |
| Tolmar Pharmaceuticals, INC. | $33.95 | 2022 | |
| Morphosys, US INC. | $33.81 | 2022-2023 | Monjuvi |
| Myriad Genetic Laboratories, INC. | $32.92 | 2022-2023 | Myrisk |
| Sun Pharmaceutical Industries INC. | $31.50 | 2025 | |
| Taiho Oncology, INC. | $30.97 | 2021-2025 | |
| Ge Healthcare | $30.09 | 2022 | |
| Karyopharm Therapeutics INC. | $29.83 | 2021-2025 | Xpovio |
| Immunocore Limited | $27.11 | 2025 | Kimmtrak |
| Heron Therapeutics, INC. | $26.81 | 2022 | |
| Mirati Therapeutics, INC. | $21.35 | 2023 | Krazati |
| Csl Behring | $20.46 | 2021 | |
| Global Blood Therapeutics, INC. | $17.64 | 2022 | |
| Cti Biopharma Corp. | $16.89 | 2023 | Vonjo |
| Syndax Pharmaceuticals, INC. | $16.64 | 2025 | |
| Recordati_rare_diseases_inc. | $16.12 | 2025 | Enjaymo |
| G1 Therapeutics, INC. | $15.26 | 2022 | |
| Pharmaessentia USA Corporation | $15.19 | 2025 | Besremi |
| Deciphera Pharmaceuticals INC. | $14.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.55 | 2023 | Xarelto |
| Epizyme, INC. | $12.74 | 2021 | |
| Adma Biomanufacturing LLC | $4.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhiannon Fahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.